Abstract Background Transcriptional coactivator with PDZ-binding motif (TAZ) has been reported to be involved in tumor progression, angiogenesis, epithelial-mesenchymal transition (EMT), glycometabolic modulation and reactive oxygen species (ROS) buildup. Herein, the underlying molecular mechanisms of TAZ-induced biological effects bladder cancer were discovered. Methods qRT-PCR, western blotti...

s of the ACM Conference on Human Factors in Computing Systems (CHI ‘03), 5 – 10 April 2003 (New York: ACM Press), pp. 942 –

To investigate the association between MLH3 Pro844Leu, Thr942Ile polymorphisms and potential linkage with the risk of cervical carcinoma and potential effect on protein function, we carried out a case-control study with 400 cervical squamous cell carcinoma, 400 CIN3 and 1200 normal controls in a Chinese population. The results showed that there was an increased risk of cervical carcinoma and CI...

Measles is an acute, communicable, disease characterized by cough, coryza, conjunctivitis, a confluent erythematous maculopapular rash and Koplik's spots. The measles virus is classified as RNA containing paramyxovirus with only one antigenic type known. Measles case fatality rates, for all age groups, have decreased because of improved socio-economic conditions and effective antibacterial ther...

BACKGROUND Pressure at the interface between bony prominences and support surfaces, sufficient to occlude or reduce blood flow, is thought to cause pressure ulcers (PrUs). Pressure ulcers are prevented by providing support surfaces that redistribute pressure and by turning residents to reduce length of exposure. OBJECTIVE We aim to determine optimal frequency of repositioning in long-term car...

Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 932 Goals and objectives 933 Participants 933 Evidence, methodology and validation 933 Concept of a "live", modular document 933 Organisation of the document 933 De® nition of COPD . . . . . . . . . . . . . . . . . . . . . . . 933 Diagnosis of COPD . . . . . . . . . . . . . . . . . . . . . . . 933 Epidemio ogy, risk factors an...